These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 28114866

  • 1. Refractory orthostatic hypotension in a patient with a spinal cord injury: Treatment with droxidopa.
    Canosa-Hermida E, Mondelo-García C, Ferreiro-Velasco ME, Salvador-de la Barrera S, Montoto-Marqués A, Rodríguez-Sotillo A, Vizoso-Hermida JR.
    J Spinal Cord Med; 2018 Jan; 41(1):115-118. PubMed ID: 28114866
    [Abstract] [Full Text] [Related]

  • 2. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, Taylor MD.
    Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
    [Abstract] [Full Text] [Related]

  • 3. Hemodynamic effects of L-threo-3,4-dihydroxyphenylserine (Droxidopa) in hypotensive individuals with spinal cord injury.
    Wecht JM, Rosado-Rivera D, Weir JP, Ivan A, Yen C, Bauman WA.
    Arch Phys Med Rehabil; 2013 Oct; 94(10):2006-12. PubMed ID: 23602882
    [Abstract] [Full Text] [Related]

  • 4. Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.
    Gupta F, Karabin B, Mehdirad A.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):15-16. PubMed ID: 28699047
    [No Abstract] [Full Text] [Related]

  • 5. Droxidopa (Northera) for neurogenic orthostatic hypotension.
    Med Lett Drugs Ther; 2015 Jun 22; 57(1471):92-3. PubMed ID: 26079764
    [No Abstract] [Full Text] [Related]

  • 6. Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Goodman BP, Claassen D, Mehdirad A.
    Clin Auton Res; 2017 Jul 22; 27(Suppl 1):17-19. PubMed ID: 28631223
    [No Abstract] [Full Text] [Related]

  • 7. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H.
    Neurology; 2018 Oct 16; 91(16):e1539-e1544. PubMed ID: 30232253
    [Abstract] [Full Text] [Related]

  • 8. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan 16; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 9. Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.
    Ho AH, Kinter CW, Wight J, Neelam AR, Krakow D.
    J Med Case Rep; 2020 Jun 20; 14(1):73. PubMed ID: 32560740
    [Abstract] [Full Text] [Related]

  • 10. Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy.
    Goodman BP, Gupta F.
    Clin Auton Res; 2017 Jul 20; 27(Suppl 1):21-23. PubMed ID: 28631222
    [No Abstract] [Full Text] [Related]

  • 11. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
    Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ, NOH301 Investigators.
    Neurology; 2014 Jul 22; 83(4):328-35. PubMed ID: 24944260
    [Abstract] [Full Text] [Related]

  • 12. Effect of L-threo-3, 4-dihydroxyphenylserine on orthostatic hypotension in a patient with spinal cord injury.
    Muneta S, Iwata T, Hiwada K, Murakami E, Sato Y, Imamura Y.
    Jpn Circ J; 1992 Mar 22; 56(3):243-7. PubMed ID: 1552652
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
    François C, Hauser RA, Aballéa S, Dorey J, Kharitonova E, Hewitt LA.
    J Med Econ; 2016 Mar 22; 19(5):515-25. PubMed ID: 26710315
    [Abstract] [Full Text] [Related]

  • 14. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM.
    Drugs; 2015 Feb 22; 75(2):197-206. PubMed ID: 25559422
    [Abstract] [Full Text] [Related]

  • 15. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
    Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G.
    Mov Disord; 2015 Apr 15; 30(5):646-54. PubMed ID: 25487613
    [Abstract] [Full Text] [Related]

  • 16. Initiation of droxidopa during hospital admission for management of refractory neurogenic orthostatic hypotension in severely ill patients.
    McDonell KE, Preheim BA, Diedrich A, Muldowney JAS, Peltier AC, Robertson D, Biaggioni I, Shibao CA.
    J Clin Hypertens (Greenwich); 2019 Sep 15; 21(9):1308-1314. PubMed ID: 31368635
    [Abstract] [Full Text] [Related]

  • 17. Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
    Kaufmann H.
    Clin Auton Res; 2017 Jul 15; 27(Suppl 1):1-3. PubMed ID: 28623419
    [No Abstract] [Full Text] [Related]

  • 18. Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol.
    Patrick K, Martin T.
    JBI Database System Rev Implement Rep; 2017 Sep 15; 15(9):2287-2294. PubMed ID: 28902695
    [Abstract] [Full Text] [Related]

  • 19. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
    Isaacson SH, Skettini J.
    Vasc Health Risk Manag; 2014 Sep 15; 10():169-76. PubMed ID: 24729712
    [Abstract] [Full Text] [Related]

  • 20. Droxidopa reduces postural sway in Parkinson disease patients with orthostatic hypotension.
    Marsili L, Duque KR, Sturchio A, Sobrero G, Premoli I, Dwivedi AK, Espay AJ, Merola A.
    Parkinsonism Relat Disord; 2022 Jun 15; 99():62-64. PubMed ID: 35605513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.